Skip to main content

Table 1 Baseline Characteristics of 32 CIP Patients

From: Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis

Characteristics Datum
Age, years, mean ± SD 64.1 ± 10.3
Male, n (%) 26 (81.3)
Current smoking, n (%) 25 (78.1)
Symptoms, n (%)
 Cough 17 (53.1)
 Dyspnea 29 (90.6)
 Fever/Fatigue/Chest pain/No symptom 11 (11.3)
Tumor location, n (%)
 Left lung 13 (40.6)
 Right lung 19 (59.4)
Tumor histology, n (%)
 squamous 9 (28.1)
 adenocarcinoma 20 (59.4)
 Squamous+ adenocarcinoma 2
 others 1 (12.5)
Initial tumor stage, n (%)
 I-II 1 (3.1)
 III-IV 31 (96.9)
ICI agents, n (%)
 pembrolizumab 21 (65.6)
 Nivolumab 6 (18.8)
 Sintilimab/durvalumab/nivolumab+ipilimumab 5 (15.6)
Surgery, n (%) 7 (21.9)
Chemotherapy, n (%) 18 (62.5)
Radiotherapy, n (%) 8 (25.0)
Radiation pneumonitis, n (%) 2 (6.3)
Prognosis, n (%)
 Survival 23 (71.9)
 Death 9 (28.1)